LDX Chart, page-1881

The underlying fundamentals seem solid tbh.

I'm seeing this as a company that is transitioning from a biomed drug discoverer, to a medi-tech equipment invention company (if that makes sense!).

Sure the reward is less - no lifechanging discoveries - but the risk drops to ZERO - as the companies who want LDX to design and produce their testing kits pay upfront, and then annual royalties.

I love this scenario, absolutely love it.

Imagine LDX designing and manufacturing 4 new tests per year, all based on their exclusive equipment.

$5,000,000 per test (as per hologic) plus annual royalties.

Look, this is very simplistic, but it's a very very good business plan.

Things like FebriDx then become the cherry on top.

This transition period will be the most challenging, but it's pretty sound IMHO